Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanz Pharma Corp Ltd (Limited Voting) CXRXF

Healthcare Drug Manufacturers - Major
Advanz Pharma Corp is an international specialty pharmaceutical company, owning or licensing, through its subsidiaries, a diversified portfolio of branded and generic prescription products. The company has two reportable segments, which consist of ADVANZ PHARMA International and ADVANZ PHARMA North America. In ADVANZ PHARMA North America segment revenue is derived from two customer groups, which includes wholesalers and authorized generic partners. In ADVANZ PHARMA International segment revenue


OTCPK:CXRXF - Post by User

Advanz Pharma Corp Ltd (Limited Voting)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by Hcgfllkpon Jan 24, 2020 4:26pm
111 Views
Post# 30596670

t

t
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities